1098 related articles for article (PubMed ID: 34747643)
1. A Single Dose of SARS-CoV-2 Vaccine Primes a Strong Humoral Immune Response in COVID-19-Recovered Patients.
Mahallawi WH; Fakher MH; Alsarani MA; Aljohani RH; Al-Mutabgani SA; Ibrahim NA
Viral Immunol; 2022 Mar; 35(2):122-128. PubMed ID: 34747643
[TBL] [Abstract][Full Text] [Related]
2. Seroepidemiological assessment of SARS-CoV-2 vaccine responsiveness and associated factors in the vaccinated community of the Casablanca-Settat Region, Morocco.
Ezzikouri S; Tajudeen R; Majidi H; Redwane S; Aqillouch S; Abdulaziz M; Aragaw M; Papa Fallah M; Sembuche S; Batcho S; Kabwe P; Gonese E; Laazaazia O; Elmessaoudi-Idrissi M; Meziane N; Ainahi A; Sarih M; Ogwell Ouma AE; Maaroufi A
Sci Rep; 2024 Apr; 14(1):7817. PubMed ID: 38570577
[TBL] [Abstract][Full Text] [Related]
3. Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status.
Eyre DW; Lumley SF; Wei J; Cox S; James T; Justice A; Jesuthasan G; O'Donnell D; Howarth A; Hatch SB; Marsden BD; Jones EY; Stuart DI; Ebner D; Hoosdally S; Crook DW; Peto TEA; Walker TM; Stoesser NE; Matthews PC; Pouwels KB; Walker AS; Jeffery K
Clin Microbiol Infect; 2021 Oct; 27(10):1516.e7-1516.e14. PubMed ID: 34111577
[TBL] [Abstract][Full Text] [Related]
4. Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
[TBL] [Abstract][Full Text] [Related]
5. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
6. Anti-SARS-CoV-2 IgA and IgG in human milk after vaccination is dependent on vaccine type and previous SARS-CoV-2 exposure: a longitudinal study.
Selma-Royo M; Bäuerl C; Mena-Tudela D; Aguilar-Camprubí L; Pérez-Cano FJ; Parra-Llorca A; Lerin C; Martínez-Costa C; Collado MC
Genome Med; 2022 Apr; 14(1):42. PubMed ID: 35449030
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2.
Pattni K; Hungerford D; Adams S; Buchan I; Cheyne CP; García-Fiñana M; Hall I; Hughes DM; Overton CE; Zhang X; Sharkey KJ
BMC Infect Dis; 2022 Mar; 22(1):270. PubMed ID: 35307024
[TBL] [Abstract][Full Text] [Related]
8. Single ChAdOx1 nCoV-19 dose elicits stronger immune response in previously infected individuals than in SARS-CoV2 naive persons.
Ebrahim F; Alboueishi A; Alhudiri IM; Tabal SA; Lamami Y; Al Dwigen S; Ashleb S; Ejenfawi N; Milad MB; Rhoumah H; El Meshri SE; Elzagheid A
Immun Inflamm Dis; 2024 Jan; 12(1):e1159. PubMed ID: 38270312
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19.
Wei J; Zhang W; Doherty M; Wallace ZS; Sparks JA; Lu N; Li X; Zeng C; Lei G; Zhang Y
BMC Med; 2023 Feb; 21(1):78. PubMed ID: 36855108
[TBL] [Abstract][Full Text] [Related]
10. MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature.
Jarius S; Bieber N; Haas J; Wildemann B
J Neurol; 2022 Oct; 269(10):5198-5212. PubMed ID: 35737110
[TBL] [Abstract][Full Text] [Related]
11. Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial.
Madhavan M; Ritchie AJ; Aboagye J; Jenkin D; Provstgaad-Morys S; Tarbet I; Woods D; Davies S; Baker M; Platt A; Flaxman A; Smith H; Belij-Rammerstorfer S; Wilkins D; Kelly EJ; Villafana T; Green JA; Poulton I; Lambe T; Hill AVS; Ewer KJ; Douglas AD
EBioMedicine; 2022 Nov; 85():104298. PubMed ID: 36229342
[TBL] [Abstract][Full Text] [Related]
12. Durability of COVID-19 humoral immunity post infection and different SARS-COV-2 vaccines.
Alroqi F; Barhoumi T; Masuadi E; Nogoud M; Aljedaie M; Abu-Jaffal AS; Bokhamseen M; Saud M; Hakami M; Arabi YM; Nasr A
J Infect Public Health; 2024 Apr; 17(4):704-711. PubMed ID: 38479067
[TBL] [Abstract][Full Text] [Related]
13. Comparison of antibody responses after the 1st and 2nd doses of COVID-19 vaccine with those of patients with mild or severe COVID-19.
Cha HH; Lim SY; Kwon JS; Kim JY; Bae S; Jung J; Kim SH
Korean J Intern Med; 2022 Mar; 37(2):455-459. PubMed ID: 35272444
[TBL] [Abstract][Full Text] [Related]
14. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
[TBL] [Abstract][Full Text] [Related]
15. An Analysis of Serological Response and Infection Outcomes Following Oxford-AstraZeneca (AZD1222) and Pfizer-BioNTech (mRNA BNT162b2) SARS-CoV-2 Vaccines in Kidney and Kidney-pancreas Transplants.
Asderakis A; Khalid U; Koimtzis G; Ponsford MJ; Szabo L; Chalklin C; Bramhall K; Grant L; Moat SJ; Humphreys IR; Jolles SR
Transplantation; 2022 Jul; 106(7):1421-1429. PubMed ID: 35283457
[TBL] [Abstract][Full Text] [Related]
16. [Humoral immunity against SARS-CoV-2 in workers of social health care centers of Castilla y León after vaccination with the BNT162b2 mRNA vaccine from Pfizer/Biontech.].
Casas Fischer R
Rev Esp Salud Publica; 2021 Oct; 95():. PubMed ID: 34690347
[TBL] [Abstract][Full Text] [Related]
17. Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens.
Moore SC; Kronsteiner B; Longet S; Adele S; Deeks AS; Liu C; Dejnirattisai W; Reyes LS; Meardon N; Faustini S; Al-Taei S; Tipton T; Hering LM; Angyal A; Brown R; Nicols AR; Dobson SL; Supasa P; Tuekprakhon A; Cross A; Tyerman JK; Hornsby H; Grouneva I; Plowright M; Zhang P; Newman TAH; Nell JM; Abraham P; Ali M; Malone T; Neale I; Phillips E; Wilson JD; Murray SM; Zewdie M; Shields A; Horner EC; Booth LH; Stafford L; Bibi S; Wootton DG; Mentzer AJ; Conlon CP; Jeffery K; Matthews PC; Pollard AJ; Brown A; Rowland-Jones SL; Mongkolsapaya J; Payne RP; Dold C; Lambe T; Thaventhiran JED; Screaton G; Barnes E; Hopkins S; Hall V; Duncan CJA; Richter A; Carroll M; de Silva TI; Klenerman P; Dunachie S; Turtle L;
Med; 2023 Mar; 4(3):191-215.e9. PubMed ID: 36863347
[TBL] [Abstract][Full Text] [Related]
18. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.
Havervall S; Marking U; Greilert-Norin N; Ng H; Gordon M; Salomonsson AC; Hellström C; Pin E; Blom K; Mangsbo S; Phillipson M; Klingström J; Hober S; Nilsson P; Åberg M; Thålin C
EBioMedicine; 2021 Aug; 70():103523. PubMed ID: 34391088
[TBL] [Abstract][Full Text] [Related]
19. Differences in SARS-CoV-2-Specific Antibody Responses After the First, Second, and Third Doses of BNT162b2 in Naïve and Previously Infected Individuals: A 1-Year Observational Study in Healthcare Professionals.
Ogrič M; Žigon P; Podovšovnik E; Lakota K; Sodin-Semrl S; Rotar Ž; Čučnik S
Front Immunol; 2022; 13():876533. PubMed ID: 35711413
[TBL] [Abstract][Full Text] [Related]
20. Real-world data on immune responses following heterologous prime-boost COVID-19 vaccination schedule with Pfizer and AstraZeneca vaccines in England.
Westrop SJ; Whitaker HJ; Powell AA; Power L; Whillock C; Campbell H; Simmons R; Warrener L; Ramsay ME; Ladhani SN; Brown KE; Amirthalingam G
J Infect; 2022 May; 84(5):692-700. PubMed ID: 35131335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
